Biology subjects

Feltham, R.

Publications and source records attributed to Feltham, R..

6 recordsLinked to original sources

bioRxiv2026

An iteratively curated CRISPR library reveals target-specific biological resistance landscapes across targeted protein degraders

Targeted protein degradation (TPD) has emerged as an increasingly powerful approach for therapeutic development and biological discovery. TPD compounds including proteolysis-targeting chimeras (PROTACs), molecular glues, and tag-targeting protein degraders (tTPD) enable rapid, selective and reversible degradation of proteins through recruitment of the ubiquitin-proteasome system (UPS). However, genome-wide CRISPR screens performed with targeted protein degraders are frequently dominated by resistance mechanisms that disrupt degrader activity, including loss of recruited E3 ligase components and broader UPS regulators. The strong selective advantage conferred by these perturbations can obscure less penetrant, biological genetic interactions that operate downstream of target degradation. To overcome this limitation, through iterative genome-wide screening and manual curation, we developed a TPD-compatible CRISPR knockout library that retains near-genome-scale coverage while excluding a focused set of genes recurrently associated with degrader failure. Across multiple degrader screens, this library reduced the dominance of UPS-associated resistance mechanisms and improved the detection and prioritization of genetic interactions linked to target biology. Using the RBM39 molecular glue degrader indisulam as a model, we identified ZMAT2 loss as a resistance mechanism that preserves RBM39 degradation but attenuates the transcriptional and splicing consequences of target depletion. Together, our work establishes a TPD-compatible CRISPR screening framework that improves the biological resolution of degrader resistance screens and facilitates the discovery of genetic dependencies operating downstream of targeted protein degradation.

genomics↗

bioRxiv2026

INTS12 Bridges Integrator and NELF to Prevent the Release of Non-processive RNA Polymerase II Complexes

Promoter-proximal RNA Polymerase II (RNAPII) pausing and the processivity are controlled by distinct modules of the Integrator complex, which together fine-tune transcription and protect against the accumulation of defective RNAPII complexes. Compromised activity of individual Integrator modules has been linked to human disease including cancer and developmental disorders, caused by defective transcription of protein-coding or small-nuclear RNAs. Despite extensive characterisation of the Integrator complex both genetically and structurally, the role of smallest member of the complex, INTS12, has remained enigmatic. Here, we uncover that INTS12 loss acts to stabilise the association between NELF and Integrator via its PHD domain and N-terminus, respectively, thus safeguarding against the release of defective RNAPII complexes. Acute degradation of INTS12 results in the selective dissociation of Integrator from the NELF-RNAPII complex which subsequently convert to their canonical paused form from which they can be released by CDK9. In the absence of INTS12 excess release of defective RNAPII via P-TEFb/SEC, loss of the ARMC5 salvage pathway and deletion of the catalytic and core Integrator subunits is toxic to cells. These findings demonstrate that there is interconversion between canonical paused RNAPII and paused-Integrator, and highlight the critical interplay between these processes and P-TEFb mediated pause-release to ensure that only transcription competent complexes are released into elongation. O_LIINTS12 degradation confers CDK9 inhibitor resistance and triggers cellular stress through a phosphatase module-independent mechanism. C_LIO_LIINTS12 stabilizes the Integrator-NELF complex through its N-terminus and PHD domain. C_LIO_LIAcute INTS12 degradation promotes aberrant release of promoter-proximal RNA polymerase II complexes. C_LIO_LIRNA polymerase II complexes released upon INTS12 loss exhibit defective elongation and reduced processivity. C_LIO_LIINTS12 loss removes Integrator from RNAPII resulting in aberrant paused-state from which it can be released by CDK9. C_LIO_LIExcess CDK9 activity and ARMC5 loss are synthetically lethal with INTS12 deficiency. C_LI

molecular biology↗

bioRxiv2025

Global analysis of cancer cell responses to USP9X inhibition

The ubiquitin specific protease (USP) enzyme USP9X is amongst the best studied human deubiquitinases (DUBs), with a myriad of described targets and cellular roles. In cancer, USP9X has been touted as both an oncogene and a tumour suppressor in different contexts, which has confounded the field and questioned its viability as a cancer target. We here describe WEHI-092, a novel piperazine-based USP9X specific small molecule inhibitor and map its binding site to a unique region in the USP9X fingers subdomain, distinct from known DUB inhibitor binding sites. Using proteomics and ubiquitinomics, we show that USP9X has a distinct set of substrates compared to USP7 indicating remarkable DUB target specificity, yet the substrate profile of USP9X varies significantly across cancer cell lines. Interestingly, we reveal a core set of 17 proteins commonly regulated by USP9X in most or all cell lines, which we consider as proximal biomarkers for USP9X inhibition. Consistent with our proteomic analyses, we show that WEHI-092 treatment arrests cells in metaphase without inducing cell death, which may account for growth suppression seen in long-term clonogenic assays in most cancer cell lines, and positions USP9X inhibitors as a new potential class of selective mitotic poisons.

cell biology↗

bioRxiv2025

A TAK1Cytokine Toxicity Checkpoint Controls Anti-Cancer Immunity

The success of cancer immunotherapies is currently limited to a subset of patients, which underscores the urgent need to identify the processes by which tumours evade immunity. Through screening a kinome-wide CRISPR/Cas9 sgRNA library we identified MAP3K7 (TAK1) as a suppressor of CD8+ T cell mediated killing. We demonstrate that TAK1 acts as a cancer-intrinsic checkpoint by integrating signals from T cell-secreted TNF and IFNy effector cytokines to elicit a cytoprotective response. This cytoprotective response profoundly limits the anti-cancer activity these key effector molecules and completely abrogates bystander killing by perforin deficient T cells. Inhibition of the TAK1 checkpoint effectively redirects the combined TNF/IFNy pathway activation to promote inflammatory cell death via RIPK1 and Caspase-8 and simultaneously amplifies the output of the IFNy pathway, thereby priming cells for cytokine-induced cell death. Mechanistically, TAK1 deficiency led to proteasomal degradation of cFLIP, enhancing the formation of Complex II and subversion of other cytoprotective responses. Targeting the TAK1 checkpoint led to profound attenuation of tumour growth in immune competent mice, with minimal impact in immune deficient counterparts. Adoptive cell therapy led to preferential elimination of TAK1 deficient clones. Collectively, our study uncovers a cancer-intrinsic checkpoint controlled by TAK1 activity that switches TNF and IFNy responses from cytoprotective to apoptosis. Cancer cells exploit this to limit cell death in the presence of the cytotoxic lymphoctye cytokines TNF and IFN{gamma} and therapeutic intervention can fully unleash the impact of these effector molecules both on the direct target and bystander cells. These findings highlight the clinical development of TAK1 biologics as a potential strategy to improve cancer immunotherapies through harnessing and enhancing the cytotoxic potential of CTL-derived cytokines. In BriefDjajawi et al. identify TAK1 as a cancer-intrinsic cytokine toxicity checkpoint that limits the efficacy of anti-cancer immune responses. Cancer cells exploit TAK1 activity to confers resistance to CD8+ T cell-derived TNF and IFN{gamma}-induced apoptosis, limiting both direct and bystander killing. Mechanistically, TAK1 loss acts through 1. cFLIP and RIPK1 to promote cell death, 2. The inactivation of pro-survival signals and 3. Via amplification of the IFNy response. Targeting of this TAK1 checkpoint enhanced anti-tumour immunity in vivo and improved adoptive cellular therapy. These findings identify a strategy employed by transformed cells to avoid destruction by inflammatory cytokines and provide new therapeutic vulnerabilities for enhancing immunotherapies. HighlightsO_LICRISPR screens identify TAK1 as a tumour-intrinsic survival checkpoint limiting destruction by CD8+ T cells. C_LIO_LITAK1 protects tumour cells from combined TNF and IFN{gamma}-induced apoptosis. C_LIO_LITAK1 loss destabilizes cFLIP, priming cells for STAT1 and RIPK1-dependent cell death. C_LIO_LITAK1 loss promotes tumour control in immune competent animals and enhances the efficacy of adoptive cell therapy. C_LI

cancer biology↗

bioRxiv2021

The inflammasome-activated cytokine IL-1 is targeted for ubiquitylation and proteasomal degradation to limit its inflammatory potential

Interleukin-1{beta} (IL-1{beta}) is activated by inflammasome-associated caspase-1 in rare autoinflammatory conditions and in wide-spread diseases. Therefore, IL-1{beta} activity must be fine-tuned to enable antimicrobial responses whilst limiting collateral damage. Here we report that precursor IL-1{beta} is rapidly turned over by the proteasome and this correlates with its decoration by K11-, K63- and K48-linked ubiquitin chains. The ubiquitylation of IL-1{beta} is not just a degradation signal triggered by inflammasome priming and activating stimuli, but also limits IL-1{beta} cleavage by caspase-1. We further demonstrate that IL-1{beta} K133 is modified by ubiquitin and forms a salt bridge with IL-1{beta} D129. Loss of IL-1{beta} K133 ubiquitylation, or disruption of the K133:D129 electrostatic interaction, stabilizes IL-1{beta}. Accordingly, IL-1{beta}K133R/K133R mice display increased precursor IL-1{beta} upon inflammasome priming and increased bioactive IL-1{beta}, both in vitro and following LPS injection in vivo. These findings reveal new mechanisms for limiting IL-1{beta} activity and safeguarding against damaging inflammation.

immunology↗

bioRxiv2020

Mechanism and inhibition of SARS-CoV-2 PLpro

Coronaviruses, including SARS-CoV-2, encode multifunctional proteases that are essential for viral replication and evasion of host innate immune mechanisms. The papain-like protease PLpro cleaves the viral polyprotein, and reverses inflammatory ubiquitin and anti-viral ubiquitin-like ISG15 protein modifications1,2. Drugs that target SARS-CoV-2 PLpro (hereafter, SARS2 PLpro) may hence be effective as treatments or prophylaxis for COVID-19, reducing viral load and reinstating innate immune responses3. We here characterise SARS2 PLpro in molecular and biochemical detail. SARS2 PLpro cleaves Lys48-linked polyubiquitin and ISG15 modifications with high activity. Structures of PLpro bound to ubiquitin and ISG15 reveal that the S1 ubiquitin binding site is responsible for high ISG15 activity, while the S2 binding site provides Lys48 chain specificity and cleavage efficiency. We further exploit two strategies to target PLpro. A repurposing approach, screening 3727 unique approved drugs and clinical compounds against SARS2 PLpro, identified no compounds that inhibited PLpro consistently or that could be validated in counterscreens. More promisingly, non-covalent small molecule SARS PLpro inhibitors were able to inhibit SARS2 PLpro with high potency and excellent antiviral activity in SARS-CoV-2 infection models.

biochemistry↗